Jazz Pharmaceuticals plc – Now Covered by Analysts at S&P Equity Research (JAZZ)
Analysts at S&P Equity Research initiated coverage on shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) in a research report issued to clients and investors on Tuesday. The firm set an “average” rating and a $42.19 price target on the stock. S&P Equity Research’s price target points to a potential downside of 72.34% from the company’s current price.
Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 1.89% on Tuesday, hitting $155.3999. The stock had a trading volume of 483,180 shares. Jazz Pharmaceuticals plc – has a 52-week low of $80.20 and a 52-week high of $176.60. The stock’s 50-day moving average is $145.4 and its 200-day moving average is $144.7. The company has a market cap of $9.358 billion and a P/E ratio of 112.72.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.13. The company had revenue of $291.23 million for the quarter, compared to the consensus estimate of $273.39 million. During the same quarter in the previous year, the company posted $1.43 earnings per share. The company’s revenue for the quarter was up 39.8% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals plc – will post $8.19 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on JAZZ. Analysts at JPMorgan Chase & Co. initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday. They set an “overweight” rating and a $190.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc – in a research note on Thursday, August 7th. They now have a $150.00 price target on the stock. Finally, analysts at Piper Jaffray raised their price target on shares of Jazz Pharmaceuticals plc – from $200.00 to $208.00 in a research note on Wednesday, August 6th. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $168.53.
In other Jazz Pharmaceuticals plc – news, EVP Suzanne Sawochka Hooper sold 1,185 shares of the stock on the open market in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $133.15, for a total value of $157,782.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with Analyst Ratings Network's FREE daily email newsletter.